Trimetazidine: Uses, Dosage, Side Effects, and Precautions

Trimetazidine is a metabolic anti-ischemic agent used primarily for the symptomatic treatment of stable angina pectoris. Unlike traditional antianginals that reduce cardiac workload (heart rate, blood pressure), trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient. This improves myocardial energy production during ischemia without significant hemodynamic effects.

Indications

• Symptomatic treatment of stable angina pectoris in adults, as add-on therapy when first-line agents (beta-blockers, calcium channel blockers) are insufficient or contraindicated.
• In some countries, also used for vertigo/tinnitus of vascular origin (off-label in others).

Dosage & Administration

• Standard dose: 35 mg twice daily (morning and evening) with meals.
• Modified-release: 75 mg once daily with breakfast.
• Renal impairment: Dose reduction required (e.g., 35 mg once daily if CrCl <30 mL/min).
• Elderly: Start at lower dose; monitor for dizziness/falls.
• Take consistently; do not stop abruptly without medical advice.

Common Side Effects

• Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea, indigestion.
• Neurological: Dizziness, headache, fatigue, sleep disturbances.
• Parkinsonian symptoms: Tremor, rigidity, bradykinesia, gait instability (rare but important; usually reversible on discontinuation).
• Skin reactions: Rash, itching.

Contraindications & Precautions

• Hypersensitivity to trimetazidine.
• Severe renal impairment (CrCl <15 mL/min).
• Parkinson's disease, parkinsonian syndromes, or other movement disorders.
• Pregnancy and breastfeeding (insufficient data).
• Use with caution in moderate renal impairment and elderly (fall risk).

Drug Interactions

No major cytochrome P450 interactions. Caution with other drugs causing parkinsonism (antipsychotics, metoclopramide). No significant interaction with anticoagulants, antiplatelets, or common cardiac drugs.

Monitoring

Assess angina symptom control. Monitor for movement disorders, especially in elderly. Renal function periodically if impaired.

Trimetazidine offers a unique metabolic approach to angina management. Its use should be guided by a cardiologist, particularly regarding movement disorder risk.